YAP1 and multiminicore myopathy: In contrast, miR-6760-5p—which antagonizes the angiogenic activity of YAP1 through the Hippo signaling pathway—is upregulated in both preclinical and clinical MMD samples, where it reduces cell proliferation, movement, and tube formation [37,47].